Form 4 for NRIX Nurix Therapeutics, Inc.
Accepted 2026-09-02 19:42:42 ET · period of report 2026-09-02 · accession 0001817199-26-000030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-02 19:42 | 2026-09-02 | NRIX | Ring Christine | CLO | M - OptEx | $8.72 | +5,787 | 14.9K | +64% | +$50.5K |
| DMT | 2026-09-02 19:42 | 2026-09-02 | NRIX | Ring Christine | CLO | S - Sale+OE | $25.76 | -5,787 | 9,110 | -39% | -$149.1K |
| DT | 2026-09-02 19:42 | 2026-09-02 | NRIX | Ring Christine | CLO | M - OptEx | $0.00 | -5,787 | 117.0K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-02 | M | A | 5,787 | $8.72 | 14,897 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. |
| 2 | Common | Common Stock | 2026-09-02 | S | D | 5,387 | $25.69 | 9,510 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. (F2) Represents the weighted average sale price. The lowest price at which shares were sold was $25.41 and the highest price at which shares were sold was $26.23. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| 3 | Common | Common Stock | 2026-09-02 | S | D | 400 | $26.64 | 9,110 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. (F3) Represents the weighted average sale price. The lowest price at which shares were sold was $26.46 and the highest price at which shares were sold was $26.73. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| 4 | Derivative | Employee Stock Option (right to buy) | 2026-09-02 | M | D | 5,787 | $0.00 | 117,037 | D | $8.72 · — to 2034-02-12 | 5,787 Common Stock | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. (F4) The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |